Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma

Exclusion Criteria

• •1. Pregnant women or women in suckling period or with Potentia Generand but not willing to take contraceptives
• •2. New York Heart Association class III or IV cardiac failure; or history of following disease in past 6 months: acute coronary syndrome, acute heart failure, severe ventricular arrhythmia
• •3. Poor hepatic function, defined as total bilirubin more than 1.5 fold of upper normal level, ALT, AST more than 2 fold of upper normal level or more than 5fold of upper normal level with hepatic involvement;Poor renal function, defined as serum creatinine more than 1.5 fold of upper normal level
• •4. CNS or meningeal involvement
• •5. intervention on myelosuppression within7 days before inclusion
• •6. patients with active bleeding
• •7. Major surgery within three weeks before inclusion
• •8. Positive HIV, syphilis,HCV, or HBV virus load(HBV DNA)\> 1×105 copies/ml;
• •9. Any psychological conditions which may disturb consent.
• •10. In any conditions which investigator considered ineligible
• •11. Known sensitivity or allergy to investigational Product.